Developers zero in on the new ‘bio-better’ strategy

The Wall Street Journal's venture blog focuses on three upstart biotechs plotting to push programs on new "bio-betters," essentially second-gen biologics that can pull the market rug out from under some blockbuster meds. It's a simple strategy: find a new biologic that is safer and more effective than a top earner already on the market-perhaps delivered more easily for greater compliance--and you have a potential billion-dollar therapy on your hands. At Femta Pharmaceuticals the target is...